Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Pancreatic Juice and Secretion01:26

Pancreatic Juice and Secretion

Pancreatic juice is a clear fluid produced by the pancreas, containing water, salts, sodium bicarbonate, and enzymes vital for digestion in the small intestine. It helps break down large molecules, facilitating nutrient absorption.
When acidic chyme from the stomach enters the duodenum, it triggers the release of secretin, a hormone that prompts pancreatic juice secretion. After a fatty meal, cholecystokinin, another hormone, stimulates gallbladder contraction and enhances enzyme-rich...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of omeprazole 40 mg once daily on intraduodenal and intragastric pH in H. pylori-negative healthy subjects.

Digestive diseases and sciences·1997
Same author

Gallbladder motility and cholecystokinin secretion during continuous enteral nutrition.

The American journal of gastroenterology·1997
Same author

A prospective follow-up study of 5669 users of lansoprazole in daily practice.

Alimentary pharmacology & therapeutics·1997
Same author

Treatment of extraintestinal complications of ulcerative colitis.

European journal of gastroenterology & hepatology·1997
Same author

Effects of medium-chain and long-chain triglycerides on antroduodenal motility and small bowel transit time in man.

Digestive diseases and sciences·1997
Same author

Effect of duodenum-preserving resection of the head of the pancreas on endocrine and exocrine pancreatic function in patients with chronic pancreatitis.

American journal of surgery·1997

Related Experiment Video

Updated: Jul 13, 2026

A Method for Mouse Pancreatic Islet Isolation and Intracellular cAMP Determination
12:33

A Method for Mouse Pancreatic Islet Isolation and Intracellular cAMP Determination

Published on: June 25, 2014

Omeprazole enhances the efficacy of pancreatin (pancrease) in cystic fibrosis.

H G Heijerman1, C B Lamers, W Bakker

  • 1Leyenburg Hospital, The Hague, The Netherlands.

Annals of Internal Medicine
|February 1, 1991
PubMed
Summary

Adding omeprazole to high-dose pancreatin significantly reduced fecal fat excretion in cystic fibrosis patients with persistent steatorrhea. This adjunct therapy improves fat absorption when a sufficient pancreatin dose is administered.

More Related Videos

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
07:04

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients

Published on: February 11, 2017

A Simple High Efficiency Protocol for Pancreatic Islet Isolation from Mice
06:56

A Simple High Efficiency Protocol for Pancreatic Islet Isolation from Mice

Published on: August 30, 2019

Related Experiment Videos

Last Updated: Jul 13, 2026

A Method for Mouse Pancreatic Islet Isolation and Intracellular cAMP Determination
12:33

A Method for Mouse Pancreatic Islet Isolation and Intracellular cAMP Determination

Published on: June 25, 2014

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
07:04

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients

Published on: February 11, 2017

A Simple High Efficiency Protocol for Pancreatic Islet Isolation from Mice
06:56

A Simple High Efficiency Protocol for Pancreatic Islet Isolation from Mice

Published on: August 30, 2019

Area of Science:

  • Gastroenterology
  • Pediatrics
  • Pharmacology

Background:

  • Cystic fibrosis (CF) patients often experience persistent steatorrhea despite pancreatic enzyme replacement therapy.
  • Pancreatic enzyme supplements aim to improve digestion and nutrient absorption in CF.
  • The efficacy of adjunct therapies in optimizing pancreatic enzyme replacement therapy requires further investigation.

Purpose of the Study:

  • To evaluate the effect of adding omeprazole to pancreatin therapy on fecal fat excretion in CF patients with persistent steatorrhea.
  • To determine if omeprazole enhances the efficacy of different doses of pancreatin.

Main Methods:

  • A double-blind, crossover study was conducted in nine CF patients with persistent steatorrhea.
  • Patients received either two or four capsules of pancreatin three times daily, with and without 20 mg of omeprazole once daily.
  • Fecal fat excretion was measured to assess treatment efficacy.

Main Results:

  • Doubling the pancreatin dose alone did not significantly reduce fecal fat excretion (mean 19.6%).
  • Adding omeprazole to the lower dose of pancreatin did not significantly improve fecal fat excretion (mean 16.4%).
  • Combining omeprazole with the higher dose of pancreatin (four capsules) significantly reduced fecal fat excretion (mean 10.7%; P < 0.01).

Conclusions:

  • Adjunct therapy with omeprazole can significantly reduce fecal fat excretion in cystic fibrosis patients.
  • The benefit of omeprazole is observed only when used in conjunction with a high dose of pancreatin.
  • Optimizing pancreatic enzyme replacement therapy in CF may involve combination strategies.